logo

Lexicon Pharmaceuticals Inc. (LXRX)



Trade LXRX now with
  Date
  Headline
6/23/2018 3:07:12 PM Lexicon Pharma Reports Positive 52-Week Results From Sotagliflozin In Tandem2 Study
6/18/2018 2:05:59 PM Wedbush Reiterates Lexicon Pharmaceuticals Inc. (LXRX) At Outperform With $42 Price Target
5/22/2018 4:33:28 PM Wedbush Reiterates Lexicon Pharmaceuticals Inc. (LXRX) At Outperform With $42 Up From $40 Price Target
5/22/2018 8:04:26 AM Sanofi Says FDA To Review Zynquista As Potential Treatment For Type 1 Diabetes
5/22/2018 8:01:47 AM Sanofi: FDA To Review Zynquista (sotagliflozin) As Potential Treatment For Type 1 Diabetes
5/7/2018 4:47:06 PM Wedbush Is Increasing Lexicon Pharmaceuticals Inc. (LXRX) FY18 Rev. Estimate To 80.4 M From 71.1 M
5/7/2018 4:46:43 PM Wedbush Is Cutting Lexicon Pharmaceuticals Inc. (LXRX) FY19 Estimate To -0.72 From -0.69
5/7/2018 4:46:26 PM Wedbush Is Raising Lexicon Pharmaceuticals Inc. (LXRX) FY18 Estimate To -1.18 From -1.43
5/7/2018 4:46:09 PM Wedbush Is Increasing Lexicon Pharmaceuticals Inc. (LXRX) Q2 18 Estimate To -0.29 From -0.38
5/4/2018 8:05:21 AM Lexicon Reports Publication Of New XERMELO (Telotristat Ethyl) Data In Clinical Therapeutics
5/3/2018 7:20:38 AM Lexicon Pharma Q1 Net Loss $42.1 Mln Or $0.40/Shr Vs Loss Of $34.9 Mln Or $0.33/Shr Last Year
4/16/2018 7:40:49 AM Wedbush Is Cutting Lexicon Pharmaceuticals Inc. (LXRX) 2018 Estimate To -1.43 From -1.22
4/16/2018 7:40:36 AM Wedbush Is Cutting Lexicon Pharmaceuticals Inc. (LXRX) 4Q18 Estimate To -0.31 From -0.27
4/16/2018 7:40:21 AM Wedbush Is Cutting Lexicon Pharmaceuticals Inc. (LXRX) 3Q18 Estimate To -0.32 From -0.29
4/16/2018 7:40:06 AM Wedbush Is Cutting Lexicon Pharmaceuticals Inc. (LXRX) 2Q18 Estimate To -0.38 From -0.31
4/16/2018 7:39:52 AM Wedbush Is Cutting Lexicon Pharmaceuticals Inc. (LXRX) 1Q18 Estimate To -0.41 From -0.35
4/16/2018 7:39:20 AM Wedbush Is Cutting Lexicon Pharmaceuticals Inc. (LXRX) 2018 Rev. Estimate To 71.1 M From 100.4 M
4/16/2018 7:39:09 AM Wedbush Is Lowering Lexicon Pharmaceuticals Inc. (LXRX) 4Q18 Rev. Estimate To 20.7 M From 31.2 M